TIRmed Pharma have begun a permeability study on their cream targeting Atopic Dermatitis, TIR-C. The study will showcase its ability to penetrate human skin – thus being a critical validation milestone. Furthermore, the study will provide data that will be used to define the concentration necessary of the active oligonucleotide TIR-01 in TIR-C.
Joanneum Research, an Austrian CRO, has been the selected partner for the study. They are an established and well-known player within the dermatological field, with a strong track record and specialized permeability models.
